Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

omega-3 acid ethyl esters (USP) · Lovaza

Small molecule · developed by Waylis Therap

Approved FDA, Nov 2004
1 Registered trials

What is omega-3 acid ethyl esters (USP)?

Omega-3 acid ethyl esters is a fish oil-derived medication that reduces serum triglyceride levels. Its mechanism is incompletely understood but may involve inhibition of triglyceride synthesis in the liver, increased fatty acid oxidation, and reduced lipogenesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Lovaza
Drug type
Small molecule
Pathways
triglyceride synthesis, lipogenesis, β-oxidation
Therapy area
Oncology
Developer
Waylis Therap
In trials of
IBRX
FDA status
Approved as Lovaza (November 10, 2004), NDA021654

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03169790 Phase 1/2 Non Hodgkin Lymphoma Withdrawn IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Hodgkin Lymphoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.